Holen Sie sich die Stockscreener-App
37.38
1.14%
0.42
Handel nachbörslich:
37.38
Schlusskurs vom Vortag:
$36.96
Offen:
$37.06
24-Stunden-Volumen:
2.27M
Relative Volume:
0.70
Marktkapitalisierung:
$10.06B
Einnahmen:
$2.17B
Nettoeinkommen (Verlust:
$521.27M
KGV:
21.12
EPS:
1.77
Netto-Cashflow:
$633.79M
1W Leistung:
-1.37%
1M Leistung:
+1.55%
6M Leistung:
-2.38%
1J Leistung:
+45.96%
1-Tages-Spanne:
$36.77
$37.67
1-Wochen-Bereich:
$36.23
$38.00
52-Wochen-Spanne:
$25.12
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Firmenname
Exelixis Inc
Sektor
Branche
Telefon
(650) 837-7000
Adresse
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Vergleichen Sie EXEL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
37.38 | 10.01B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2024-09-19 | Eingeleitet | UBS | Neutral |
| 2024-04-11 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Eingeleitet | BTIG Research | Buy |
| 2023-12-15 | Eingeleitet | Citigroup | Buy |
| 2023-09-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-22 | Bestätigt | Oppenheimer | Outperform |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-09 | Eingeleitet | Wells Fargo | Overweight |
| 2023-01-26 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-11-03 | Fortgesetzt | Jefferies | Buy |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Sell |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-18 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Eingeleitet | Goldman | Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Underweight |
| 2018-05-11 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-16 | Bestätigt | SunTrust | Buy |
| 2017-09-22 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-09-12 | Bestätigt | Needham | Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Buy |
| 2017-03-31 | Eingeleitet | Needham | Buy |
| 2017-03-16 | Eingeleitet | Oppenheimer | Perform |
| 2017-02-28 | Herabstufung | Stifel | Buy → Hold |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2016-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Bestätigt | Stifel | Buy |
Alle ansehen
Exelixis Inc Aktie (EXEL) Neueste Nachrichten
Exelixis’ Strategic Momentum in Oncology Innovation - AInvest
Transcript : Exelixis, Inc. Presents at Citi's Biopharma Back to School Conference, Sep-03-2025 03 - MarketScreener
Exelixis (EXEL): Leveraging ZANZA's Breakthrough and Strong Cash Flow for Long-Term Value Creation - AInvest
Exelixis Presents at 2025 Wells Fargo Healthcare Conference: Key Takeaways and Insights - AInvest
Prostate Cancer Pipeline Analysi, 2025 by DelveInsight | Pfizer, Janssen Pharmaceutical, POINT Biopharma, Tavanta Therapeutics, Exelixis, Astellas Pharma Inc., Antev, ORCA Therapeutics, Regeneron Phar - Barchart.com
Transcript : Exelixis, Inc. Presents at Wells Fargo 20th Annual Healthcare Conference 2025, Sep-03-2025 12 - MarketScreener
Building trade automation scripts for Exelixis Inc.Rate Cut & Daily Profit Maximizing Trade Tips - Newser
Breakout Watch: Is Exelixis Inc. a play on infrastructure spendingM&A Rumor & Smart Allocation Stock Reports - khodrobank.com
Take Profit: Can Exelixis Inc. lead its sector in growthPortfolio Return Report & AI Powered Buy and Sell Recommendations - khodrobank.com
Ranking Exelixis Inc. among high performing stocks via tools2025 Price Momentum & Verified Swing Trading Watchlists - Newser
Using data models to predict Exelixis Inc. stock movementWeekly Stock Report & High Accuracy Swing Trade Signals - Newser
Sector ETF performance correlation with Exelixis Inc.2025 Analyst Calls & Consistent Profit Trade Alerts - Newser
Exelixis Inc. stock retracement – recovery analysisInflation Watch & Free Risk Controlled Daily Trade Plans - Newser
Using Bollinger Bands to evaluate Exelixis Inc.July 2025 Update & Consistent Profit Alerts - Newser
Analyzing Exelixis Inc. with risk reward ratio chartsJuly 2025 Recap & High Conviction Buy Zone Picks - Newser
What is the earnings history of Exelixis Inc.Quarterly Trade Summary & Expert Curated Trade Setups - khodrobank.com
How to interpret RSI for Exelixis Inc. stockJuly 2025 Weekly Recap & Stepwise Entry/Exit Trade Alerts - Newser
Can Exelixis Inc. recover in the next quarterDollar Strength & Growth Focused Investment Plans - Newser
Exelixis, Inc. (EXEL) Halts Phase 3 STELLAR-305 Trial - MSN
Is Exelixis Inc. stock forming a cup and handleJuly 2025 Trade Ideas & Consistent Growth Equity Picks - khodrobank.com
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm - The Globe and Mail
Will Exelixis Inc. benefit from AI trendsGap Down & Real-Time Buy Zone Alerts - khodrobank.com
Institutional scanner results for Exelixis Inc.2025 Volatility Report & Weekly Consistent Profit Watchlists - Newser
Exelixis Q2 net product revenues miss consensus estimate by 2%. - AInvest
What’s Exelixis Inc.’s historical return2025 Earnings Surprises & Fast Gaining Stock Strategy Reports - khodrobank.com
Evaluating Exelixis Inc. with trendline analysisPortfolio Value Summary & Low Volatility Stock Suggestions - Newser
Exelixis Inc. Breaks Below Key Support Level getLinesFromResByArray error: size == 0 - kangso.co.kr
Will breakout in Exelixis Inc. lead to full recoveryMarket Risk Analysis & Pattern Based Trade Signal System - Newser
Is Exelixis Inc. stock bottoming out2025 Stock Rankings & Weekly High Return Stock Opportunities - Newser
Full technical analysis of Exelixis Inc. stockJuly 2025 Outlook & Long-Term Safe Investment Ideas - Newser
Exelixis Announces New Executive VP for R&D - MSN
What candlestick patterns are forming on Exelixis Inc.Weekly Volume Report & Fast Entry and Exit Trade Plans - Newser
Signal strength of Exelixis Inc. stock in tech scannersMarket Risk Analysis & Weekly Watchlist of Top Performers - Newser
Developing predictive dashboards with Exelixis Inc. dataMarket Movement Recap & Free Technical Pattern Based Buy Signals - Newser
Should you wait for a breakout in Exelixis Inc.Portfolio Gains Summary & Daily Growth Stock Investment Tips - Newser
What Fibonacci levels say about Exelixis Inc. reboundJuly 2025 Opening Moves & Real-Time Buy Signal Alerts - Newser
Statistical indicators supporting Exelixis Inc.’s strengthJuly 2025 Price Swings & Breakout Confirmation Alerts - Newser
Exelixis to Present at Investor Conferences in September - AInvest
Will Exelixis Inc. stock go up soonMarket Volume Summary & AI Driven Stock Movement Reports - Newser
Identifying reversal signals in Exelixis Inc.2025 Technical Overview & Expert Verified Stock Movement Alerts - Newser
Finanzdaten der Exelixis Inc-Aktie (EXEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Exelixis Inc-Aktie (EXEL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| WYSZOMIERSKI JACK L | Director |
Jun 03 '25 |
Sale |
43.09 |
7,535 |
324,683 |
358,882 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):